Sign in or create an account to add this stock to your watchlist.
About Repligen (NASDAQ:RGEN)
Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RGEN
CUSIP75991610
Phone781-250-0111
Debt
Debt-to-Equity Ratio0.17
Current Ratio12.22
Quick Ratio10.25
Price-To-Earnings
Trailing P/E Ratio61.74
Forward P/E Ratio60.00
P/E Growth2.84
Sales & Book Value
Annual Sales$141.24 million
Price / Sales13.18
Cash Flow$0.8652 per share
Price / Cash49.24
Book Value$13.58 per share
Price / Book3.14
Profitability
EPS (Most Recent Fiscal Year)$0.69
Net Income$28.35 million
Net Margins18.48%
Return on Equity6.06%
Return on Assets4.69%
Miscellaneous
Employees476
Outstanding Shares43,690,000
Repligen (NASDAQ:RGEN) Frequently Asked Questions
What is Repligen's stock symbol?
Repligen trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen's earnings last quarter?
Repligen (NASDAQ:RGEN) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.15 by $0.02. The biotechnology company earned $44.80 million during the quarter, compared to analysts' expectations of $43.88 million. Repligen had a return on equity of 6.06% and a net margin of 18.48%. Repligen's revenue was up 46.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.15 earnings per share. View Repligen's Earnings History.
When is Repligen's next earnings date?
What guidance has Repligen issued on next quarter's earnings?
Repligen issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share guidance of $0.69-0.73 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.70. The company issued revenue guidance of $182-188 million, compared to the consensus revenue estimate of $183.48 million.
What price target have analysts set for RGEN?
7 equities research analysts have issued 12-month target prices for Repligen's shares. Their forecasts range from $40.00 to $50.00. On average, they anticipate Repligen's stock price to reach $44.5714 in the next twelve months. View Analyst Ratings for Repligen.
Who are some of Repligen's key competitors?
Some companies that are related to Repligen include Bio-Techne (TECH), CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Editas Medicine (EDIT), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX) and Iovance Biotherapeutics (IOVA).
Who are Repligen's key executives?
Repligen's management team includes the folowing people:
- Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 54)
- Mr. Jon K. Snodgres, CFO, Sec. & Principal Accounting Officer (Age 52)
- Mr. Steve Curran, VP of Global Operations
- Ms. Sondra S. Newman, Sr. Director Investor Relations
- Mr. Stephen Tingley, VP of Sales
Has Repligen been receiving favorable news coverage?
Media coverage about RGEN stock has been trending somewhat positive this week, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Repligen earned a news sentiment score of 0.22 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.67 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Repligen's major shareholders?
Repligen's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.28%), OppenheimerFunds Inc. (4.55%), Dimensional Fund Advisors LP (2.32%), Federated Investors Inc. PA (2.13%), Stephens Investment Management Group LLC (2.13%) and Palisade Capital Management LLC NJ (1.74%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.
Which institutional investors are selling Repligen stock?
RGEN stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Wells Fargo & Company MN, Allianz Asset Management GmbH, Sei Investments Co., Citigroup Inc., RMB Capital Management LLC, Blair William & Co. IL and Schwab Charles Investment Management Inc.. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Howard Benjamin, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.
Which institutional investors are buying Repligen stock?
RGEN stock was purchased by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Dimensional Fund Advisors LP, Russell Investments Group Ltd., Federated Investors Inc. PA, UBS Group AG, Pier Capital LLC, Cortina Asset Management LLC and Palisade Capital Management LLC NJ. View Insider Buying and Selling for Repligen.
How do I buy shares of Repligen?
Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repligen's stock price today?
One share of RGEN stock can currently be purchased for approximately $42.60.
How big of a company is Repligen?
Repligen has a market capitalization of $1.86 billion and generates $141.24 million in revenue each year. The biotechnology company earns $28.35 million in net income (profit) each year or $0.69 on an earnings per share basis. Repligen employs 476 workers across the globe.
How can I contact Repligen?
Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]
MarketBeat Community Rating for Repligen (RGEN)
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Repligen (NASDAQ:RGEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Repligen in the last 12 months. Their average twelve-month price target is $44.5714, suggesting that the stock has a possible upside of 4.63%. The high price target for RGEN is $50.00 and the low price target for RGEN is $40.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.86 | 2.86 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $44.5714 | $44.5714 | $44.5714 | $45.00 |
| Price Target Upside: | 4.63% upside | 28.89% upside | 28.89% upside | 29.61% upside |
Repligen (NASDAQ:RGEN) Consensus Price Target History
Repligen (NASDAQ:RGEN) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Repligen (NASDAQ:RGEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Repligen (NASDAQ RGEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.40%
Institutional Ownership Percentage: 88.22%
Repligen (NASDAQ RGEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/16/2018 | Roy T Eddleman | Major Shareholder | Sell | 118,850 | $42.07 | $5,000,019.50 | |  |
| 5/11/2018 | Karen A Dawes | Director | Sell | 20,000 | $41.80 | $836,000.00 | 114,957 | |
| 5/9/2018 | Nicolas Barthelemy | Director | Sell | 26,500 | $40.54 | $1,074,310.00 | 27,988 | |
| 5/9/2018 | Roy T Eddleman | Major Shareholder | Sell | 120,000 | $40.62 | $4,874,400.00 | | |
| 3/8/2018 | Thomas F Ryan Jr | Director | Sell | 4,696 | $36.16 | $169,807.36 | 9,700 | |
| 1/22/2018 | Anthony Hunt | CEO | Sell | 8,970 | $35.95 | $322,471.50 | 83,613 | |
| 12/14/2017 | Howard Benjamin | VP | Sell | 12,729 | $35.34 | $449,842.86 | 36,554 | |
| 3/21/2017 | Karen A Dawes | Director | Sell | 2,521 | $34.12 | $86,016.52 | 95,764 | |
| 3/20/2017 | Howard Benjamin | VP | Sell | 12,216 | $34.62 | $422,917.92 | 36,124 | |
| 3/20/2017 | Thomas F Ryan Jr | Director | Sell | 4,000 | $34.83 | $139,320.00 | 12,594 | |
| 3/17/2017 | Jon Snodgres | CFO | Sell | 1,909 | $34.91 | $66,643.19 | 23,789 | |
| 11/28/2016 | Anthony Hunt | CEO | Sell | 5,000 | $33.12 | $165,600.00 | 68,342 | |
| 9/14/2016 | Thomas F Ryan Jr | Director | Sell | 2,700 | $32.58 | $87,966.00 | 9,394 | |
| 6/30/2016 | Thomas F Ryan Jr | Director | Sell | 5,000 | $26.60 | $133,000.00 | 12,094 | |
| 6/28/2016 | Thomas F Ryan Jr | Director | Sell | 10,000 | $24.59 | $245,900.00 | 27,094 | |
| 5/11/2016 | Howard Benjamin | VP | Sell | 2,889 | $26.72 | $77,194.08 | 18,626 | |
| 6/9/2015 | Howard Benjamin | VP | Sell | 35,000 | $38.14 | $1,334,900.00 | | |
| 5/11/2015 | Walter C Herlihy | CEO | Sell | 104,569 | $37.94 | $3,967,347.86 | | |
| 5/8/2015 | Thomas F Ryan Jr | Director | Sell | 20,000 | $37.19 | $743,800.00 | | |
| 3/23/2015 | Walter C Herlihy | CEO | Sell | 24,536 | $31.78 | $779,754.08 | | |
| 3/19/2015 | James R Rusche | SVP | Sell | 14,650 | $33.30 | $487,845.00 | | |
| 3/19/2015 | Thomas F Ryan Jr | Director | Sell | 10,000 | $32.62 | $326,200.00 | | |
| 3/19/2015 | Walter C Herlihy | CEO | Sell | 49,695 | $33.08 | $1,643,910.60 | | |
| 3/18/2015 | Howard Benjamin | VP | Sell | 15,795 | $32.63 | $515,390.85 | | |
| 11/19/2014 | Walter C Herlihy | CEO | Sell | 51,386 | $23.43 | $1,203,973.98 | | |
| 11/13/2014 | Thomas F Ryan Jr | Director | Sell | 10,000 | $23.81 | $238,100.00 | | |
| 11/11/2014 | Howard Benjamin | VP | Sell | 30,000 | $23.56 | $706,800.00 | | |
| 11/10/2014 | Michael A Griffith | Director | Sell | 23,342 | $22.90 | $534,531.80 | | |
| 8/13/2014 | Howard Benjamin | VP | Sell | 40,000 | $20.34 | $813,600.00 | | |
| 6/27/2014 | Thomas F Ryan Jr | Director | Sell | 10,000 | $22.41 | $224,100.00 | | |
| 6/24/2014 | Thomas F Ryan Jr | Director | Sell | 10,000 | $21.78 | $217,800.00 | | |
| 6/11/2014 | Walter C Herlihy | CEO | Sell | 60,335 | $20.11 | $1,213,336.85 | | |
| 6/9/2014 | James R Rusche | SVP | Sell | 30,000 | $20.19 | $605,700.00 | | |
| 6/6/2014 | Daniel P Witt | SVP | Sell | 47,709 | $20.56 | $980,897.04 | | |
| 4/15/2014 | Daniel P Witt | SVP | Buy | 10,000 | $3.05 | $30,500.00 | | |
| 8/8/2013 | James R Rusche | SVP | Sell | 30,000 | $10.01 | $300,300.00 | | |
| 6/21/2013 | Karen A Dawes | Director | Buy | 1,000 | $7.70 | $7,700.00 | | |
| 5/17/2013 | Thomas F Ryan Jr | Director | Sell | 21,000 | $8.97 | $188,370.00 | | |
| 5/15/2013 | Thomas F Ryan Jr | Director | Sell | 86,039 | $9.01 | $775,211.39 | | |
| 5/15/2013 | Walter C Herlihy | CEO | Sell | 40,000 | $8.97 | $358,800.00 | | |
| 9/21/2012 | Glenn L Md Cooper | Director | Buy | 10,000 | $6.09 | $60,900.00 | | |
| 8/16/2012 | Michael A Griffith | Director | Buy | 2,000 | $4.88 | $9,760.00 | | |
(Data available from 1/1/2013 forward)
Repligen (NASDAQ RGEN) News Headlines
| Source: |
|
Repligen (NASDAQ:RGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Repligen (NASDAQ:RGEN) Income Statement, Balance Sheet and Cash Flow Statement
Repligen (NASDAQ RGEN) Stock Chart for Monday, May, 21, 2018
Loading chart…
